Strong financial results for Takeda in third quarter

3 February 2022

In the third Japanese financial quarter ended December 2021, Takeda Pharmaceutical (TYO: 4502) delivered year-to-date revenues of 2,700 billion yen ($23.5 billion), an increase of 11% on the same period from last year.

Net profit was also up, at 241 billion yen, an increase of 34.9%, while earnings per share (EPS) stood at 154 yen, an increase of 34.5%.

Revenue drivers for the newly-enlarged pharma giant included the firm’s 14 global brands, which saw an aggregate reported revenue of 1,073 billion yen, growth of 12%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK